Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name MCS110
Trade Name
Synonyms Lacnotuzumab
Drug Descriptions

Lacnotuzumab (MCS110) is a monoclonal antibody that binds CSF1 and prevents receptor binding and subsequent receptor activation, and leads to reduction of tumor-related bone destruction (Cancer Res; 2009 Apr 18-22; Abstract nr DDT02-2).

DrugClasses CSF1 Antibody 2
CAS Registry Number 1831128-32-5
NCIT ID C80044


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel Cyclophosphamide Doxorubicin MCS110 Paclitaxel 0 1
Dabrafenib + MCS110 + Trametinib Dabrafenib MCS110 Trametinib 0 1
Ieramilimab + MCS110 + Spartalizumab Ieramilimab MCS110 Spartalizumab 0 1
MCS110 MCS110 0 2
MCS110 + Spartalizumab MCS110 Spartalizumab 0 1

Additional content available in CKB BOOST